Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01313429CT.gov Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Pleural Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Allogenic Tumor Cell Vaccine (K562) (this asset) | National Cancer Institute (NCI) | P1 | CC · 43 |
| Cyclophosphamide | Memorial Sloan Kettering Cancer Center | P1/2 | CCC |
| Pembrolizumab | Memorial Sloan Kettering Cancer Center | P1/2 | CCC |
| Icasp9M28Z T Cell Infusions | Memorial Sloan Kettering Cancer Center | P1/2 | CCC |
| Celecoxib | National Cancer Institute (NCI) | P1 | CC |
| Fapi-46 | Jonsson Comprehensive Cancer Center | P1 | CC |
| Epigenetically Modified Autologous Tumor | National Cancer Institute (NCI) | P1 | CC |
| Doxepin | Mayo Clinic | P2 | C |
| mt027 | Suzhou Maximum Bio-tech Co., Ltd. | P1 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Allogenic Tumor Cell Vaccine (K562) in Pleural Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/allogenic-tumor-cell-vaccine-k562-pleural-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →